Neuros Medical has raised $56 million in an oversubscribed Series D round to support U.S. commercialization of its Altius nerve stimulation system. Cleared by the FDA last year, Altius provides on-demand electrical nerve stimulation to help adult amputees manage chronic phantom and residual limb pain by inhibiting pain signals at their source.
The patient-controlled system includes a nerve cuff electrode and implantable pulse generator for targeted pain relief sessions. EQT Life Sciences led the round, with participation from existing investors including US Venture Partners and Amzak Health. Neuros Medical plans to scale its commercial reach and offer a non-opioid alternative for post-amputation pain.
Follow MEDWIRE.AI for the latest in neurostimulation technologies.
